IDH1 and acute myeloid leukemia: Ivosidenib was also evaluated in the phase III AGILE trial combined with hypomethylating agent azacitidine (AZA) in patients with newly diagnosed IDH1-mutated AML, compared to the use of AZA and placebo [92].